Aurobindo Pharma achieves promising results for breast cancer biosimilar in Phase 3 trial
Aurobindo Pharma has announced positive results from a Phase 3 clinical trial of its breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin), developed by its subsidiary, Curateq Biologics. The clinical trial demonstrated that BP02 has a comparable efficacy and safety profile to Herceptin. The trial was a multi-center, randomized, double-blind study involving women […]